Session 15: Diagnosing & Delivery News of Cardiometabolic Disease Diagnosis

Wednesday, November 2, 2022, 12:30 PM - 1:45 PM, Webinar (Online)

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician (1.00 hours)

Date and Time: Session 15: Wednesday, November 2, 2022 @ 12:30pm-1:45pm PST 
Zoom Webinar ID: 976 0959 8851 
Webinar Link: https://washington.zoom.us/j/97609598851

Talk Title: Diagnosing and Delivering News of Cardiometabolic Disease Diagnosis

To go back to the main course page, please click here.

Talk Objectives:

• Recognize the diagnosis criteria for cardiometabolic disease.
• Be able to discuss the diagnosis of obesity, pre-diabetes mellitus, diabetes, hypertension, and hyperlipidemia diagnosis with patients.
• Calculate ASCVD risk and discuss it with patients.

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this  for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE #: 0130-9999-22-471-H01-P
0130-9999-22-471-L01-P

Dr. Erin Michos is an Associate Professor in the Division of Cardiology at the Johns Hopkins School of Medicine, with joint appointment in Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Associate Director of Preventive Cardiology

Dr. Michos is an internationally known expert in Preventive Cardiology and Women’s Health, having authored >570 publications and 10 book chapters. Her research involves (1) Cardio-Obstetrics and Women’s Cardiovascular Health; (2) coronary artery calcium, inflammation and other biomarkers; (3) Lipids; and (4) Diabetes & Cardio-metabolic disease.

She is the co-Editor-in-Chief for the American Journal of Preventive Cardiology, an Associate Editor for Circulation, a member of the Board of Directors for the American Society of Preventive Cardiology (ASPC), and a member of the American College of Cardiology (ACC) Prevention Leadership Council. She is also a member of ACC’s Clinical Quality Approval Committee (CPAC). Dr. Michos has also held several leadership positions within the American Heart Association (AHA) including being a member of the AHA Funding Committee.

Dr. Michos is a co-investigator in several NIH-funded studies including the Multi-Ethnic Study of Atherosclerosis (MESA) and the Atherosclerosis Risk in Communities (ARIC) cohorts. She is the Training Director for three AHA Strategic Focused Research Networks. She has mentored over 60 individuals in her career and was the recipient of 2 mentoring awards at Johns Hopkins University.

Dr. Michos completed medical school at Northwestern University, Internal Medicine residency and Cardiology fellowship at Johns Hopkins Hospital, and a Masters of Health Science degree at Johns Hopkins School of Public Health.

Speaker Disclosure(s): Advisory Board of AstraZeneca, Amarin, Amgen, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, Pfizer. Educational talks (NOT promotional) with Edwards, Medtronic.

Planner Disclosure(s):

• Dr. Nicole Ehrhardt, MD is on the Advisory board for Dexcom and Novo Nordisk; Educational Grant: Novo Nordisk and Merck; Investigator: Dexcom
• Dr. Savitha Subramanian, MD is on the advisory board for Abbott Diabetes Care and was formerly on the Advisory board for Akcea Therapeutics and Amarni.
• Laura Montour, MD: none
• Lorena Casas-Wright, MD: none
• Nayan Arora, MD: none

All relevant financial relationships have been mitigated.

Mitigation of Relevant Financial Relationships

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Wednesday, November 2, 2022

We would like to acknowledge an educational grant from: NovoNordisk and EDAN